Postural Orthostatic Tachycardia Syndrome
44
8
14
19
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
6.8%
3 terminated out of 44 trials
86.4%
-0.1% vs benchmark
11%
5 trials in Phase 3/4
47%
9 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (44)
NC Testing in LC & POTS
Compression Garments in the Community With POTS
CAlgary SAlt for POTS
Low Dose Naltrexone Use in Patients With POTS
Paediatric Syncope in the Emergency Department
Postural Sway and Counterpressure Maneuvers for Pediatric Syncope
Using Mirabegron to Increase BP in Patients With POTS
Transdermal Vagal Stimulation for POTS
Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome
Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
Breathing Device in Postural Orthostatic Tachycardia Syndrome (POTS)
Autoimmune Basis for Postural Tachycardia Syndrome
Non-invasive Vagal Neurostimulation (nVNS) in Adolescents With Postural Orthostatic Tachycardia Syndrome (POTS)
Assessment of Antibodies and Inflammatory Markers in Postural Tachycardia Syndrome
Pathophysiology of Orthostatic Intolerance
Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
The Long COVID-19 Wearable Device Study
Physical Training in Patients With POTS After Covid-19
A Shared Medical Appointment Intervention for Quality of Life Improvement in POTS